CIK 0001638097 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in L3 · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 42000 | 0 | 134000 | |
| Net income (USD) | -8.9 M | -13.1 M | -12.2 M | |
| Diluted EPS (USD/shares) | 0.25 | 0.31 | 0.45 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-14 | DEF 14A | DEF 14A | 2026-10-14 |
| 2026-10-06 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-10-06 |
| 2026-09-23 | PRE 14A | PRE 14A | 2026-09-23 |
| 2026-08-28 | EFFECT | EFFECT items ,, | |
| 2026-08-28 | 424B3 | 424B3 | |
| 2026-08-21 | S-3 | S-3 | |
| 2026-08-21 | 3 | 3 | 2026-08-18 |
| 2026-08-18 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-08-18 |
| 2026-08-12 | D | D items 06b | |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | S-8 | S-8 | |
| 2026-08-07 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-07 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-08-07 |
| 2026-08-04 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-04 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-04 | SCHEDULE 13D | SCHEDULE 13D | |
| 2026-08-04 | SCHEDULE 13G | SCHEDULE 13G |
Forms on file (last 1,000): 4 101, 6-K 72, 8-K 49, 3 20, CORRESP 19, SC 13G/A 17, UPLOAD 15, 10-Q 14. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ENTX (0.002 USD), /gw/filings/filings?ticker=ENTX&form=8-K, /gw/filings/facts?ticker=ENTX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange